A Phase 2a Randomized Controlled Trial of MIB-626 (ß Nicotinamide Mononucleotide, NMN) vs. Placebo in Adults with COVID-19 Infection and Early Acute Kidney Injury

Grant

Total Award Amount

  • 162500.00
  • Direct Costs

  • 125000.00
  • Sponsor Award Id

  • Contributor

  • Tapan Mehta   Principal Investigator